Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 3/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | FNTA | P49354 | 1/20 | 0.30 |
| ▸ | FNTB | P49356 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601041 | 0.85 | ADORA2A (0.32) | FNTAFNTB | |
| SCHEMBL23577253 | 0.84 | ALPL (0.38) | ACLYERN1MAT2AKDREPHB4 | |
| SCHEMBL31229686 | 0.82 | KDR (0.39) | ACLYERN1KDREPHB4TEK | |
| SCHEMBL23601031 | 0.82 | KDR (0.39) | ACLYERN1KDREPHB4TEK | |
| SCHEMBL29909416 | 0.78 | KDM1A (0.36) | KDREPHB4KMT2A | |
| SCHEMBL31169401 | 0.74 | CYP11B1 (0.32) | — | |
| SCHEMBL23601045 | 0.74 | CYP11B1 (0.32) | — | |
| SCHEMBL23576704 | 0.74 | TP53 (0.38) | MAT2AFNTAFNTBMAPTKMT2A | |
| SCHEMBL23601277 | 0.74 | MAT2A (0.36) | MAT2AFNTAFNTBKMT2A | |
| SCHEMBL23601712 | 0.73 | MAT2A (0.36) | MAT2AFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ACLY 2887/4885ERN1 281/4885MAT2A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.